Skip to main content

Table 4 Regression Analysis for Grade I- Postoperative Grade I Ileus with total cohort

From: Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study

 

Univariate analysis

Multivariate analysis

OR

OR 95% CI

p

OR

OR 95%CI

p

Gender (M/F)

1.77

0.97–3.1

0.06

   

Age at surgery(years)

1.01

0.94–1.02

0.94

   

BMI (kg/m2)

0.11

0.41–2.7

0.55

   

Preoperative wt loss

(> 10 lb)a

1.05

0.41–2.7

0.92

   

Disease duration (mos)

0.99

0.99–1.02

0.59

   

Smoking

Never

Prior

0.97

0.47–2.0

0.97

   

Current

0.67

0.79–5.7

0.72

   

Disease extent

E2 Left-sided colitis

E3 Pancolitis

1.45

066–3.40

0.34

   

Disease severity

S2 Moderate UC

S3 Severe UC

1.12

0.60–2.12

0.72

   

Disease activity

Chronic

Acute

2.83

1.05–7.67

0.04

3.09

1.11–8.61

0.03

Medication history

Steroids

0.92

0.59–1.98

0.92

   

6-MP or MTX

0.53

0.29–0.97

0.04

0.56

0.28–1.07

0.08

IPAA stages

Total abdominal colectomy

+end stoma

Protectomy + IPAA with ileostomy

1.24

0.65–2.40

0.51

   

Operation type

Open

laparoscopy

0.53

0.28–0.98

0.04

0.54

0.27–1.06

0.07

Preoperative labs

Leukocyte (×103/uL)

1.00

1.00–1.00

0.45

   

Platelet (×103/uL)

1.01

0.99–1.00

0.34

   

Albumin (g/dL)

0.82

0.40–1.65

0.58

   

Biologic agent

None

Anti-TNF

1.76

0.83–3.73

0.14

2.45

1.08–5.59

0.03

Vedolizumab

3.15

1.08–9.2

0.04

4.71

1.51–14.70

0.01

  1. OR odds ratio, CI confidence interval, BMI body mass index, 6-MP 6-mercaptopurine, MTX methotrexate, CSA cyclosporine A, IPAA ileal pouch-anal anastomosis, TNF tumor necrosis factor